Compounds > trimethoprim--sulfamethoxazole-drug-combination

trimethoprim--sulfamethoxazole-drug-combination and Depressive-Disorder--Major

trimethoprim--sulfamethoxazole-drug-combination has been researched along with Depressive-Disorder--Major* in 2 studies

Other Studies

2 other study(ies) available for trimethoprim--sulfamethoxazole-drug-combination and Depressive-Disorder--Major

Article	Year
Trimethoprim-Sulfamethoxazole-Induced Exacerbation of Anxiety and Depression. The primary care companion for CNS disorders, 2018, Aug-09, Volume: 20, Issue:4 Topics: Aged; Anti-Infective Agents, Urinary; Anxiety; Depression; Depressive Disorder, Major; Female; Humans; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections	2018
Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Therapeutic drug monitoring, 2013, Volume: 35, Issue:3 : We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 1/2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 due to a genetic deficit and (2) inhibition of CYP2C9 by cotrimoxazole. Topics: Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Drug Interactions; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination; Venlafaxine Hydrochloride	2013

Article

Year

Trimethoprim-Sulfamethoxazole-Induced Exacerbation of Anxiety and Depression.

The primary care companion for CNS disorders, 2018, Aug-09, Volume: 20, Issue:4

Topics: Aged; Anti-Infective Agents, Urinary; Anxiety; Depression; Depressive Disorder, Major; Female; Humans; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections

2018

Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.

Therapeutic drug monitoring, 2013, Volume: 35, Issue:3

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 due to a genetic deficit and (2) inhibition of CYP2C9 by cotrimoxazole.

Topics: Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Drug Interactions; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination; Venlafaxine Hydrochloride

2013